Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Mark Skolnick

Walter Gilbert

Kevin Kimberlin

Peter D. Meldrum

Myriad Genetics, Inc.

American Esoteric Laboratories (AEL) is a laboratory providing diagnostic testing services. It is self-described as being accredited by the College of American Pathologists and licensed by the State of Tennessee.

American Esoteric Laboratories (AEL)

Genome Medical is a leading genomic medicine delivery company, providing easy access to expert genetic counseling and personalized health care through a digital health technology platform.

Randy Scott

Robert Green

Lisa Alderson

Genome Medical

Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.

Ortho Clinical Diagnostics Holdings plc

Myriad Genetics focuses on advancing health through genetic testing, providing insights for hereditary cancer risk assessment, prenatal care, cancer management, and mental health treatment. The company self-describes its role in precision medicine.

Myriad Genetics

Myriad UroSuite™

Personalized Medicine & Companion Diagnostics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. 

RainDance Technologies

Whether a woman has a personal or family history of cancer, genetic testing may help them uncover information that can help guide medical management decisions if they are at higher risk for cancer. Melissa Gonzales, President of Women's Health at Myriad, authored this Healthcare Business Today article on three genetic testing trends advancing women’s health in 2024. 

Here's a sneak peek:
📈 Bridging The Awareness Gap About Family Health History 
📈 New Research, Evolving Guidelines Drive Push For Genetic Testing
📈 Genetic Testing Fears Declining

Learn more: https://lnkd.in/gVESf_pK 

#genetictesting #womenshealth 

Join us for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor

Please join Myriad Genetics for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor
 

We're excited to announce that we have entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. Learn more: https://lnkd.in/edYjC4_V

“With this acquisition, we’re deepening our commitment to our oncology business while also generating a more effective way to scale and grow our tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities,” said Paul Diaz, president and CEO, Myriad Genetics. “We’d like to thank our longstanding partners at Intermountain Health for the important progress they’ve made in advancing precision oncology care. We look forward to continuing to build on this foundation to provide comprehensive genomic profiling options to the Intermountain Health System and its patients and providers that can help guide clinical care and improve patient outcomes.”

#oncology #genetictesting

What a year 2023 was - promoted to senior rep, team MVP & another President’s Club win. 

NSM in Tampa last week was great, loved getting to see so many friends and colleagues and to plan for a great 2024! ✨Grateful to work for Myriad Genetics and with my incredible manager & Mighty Mid team 🧬I love the work I’m able to do everyday - to directly impact the lives of many women (and men) through the testing Myriad provides. Here’s to 2024!

Service is love in action. It has the power to bring communities together, help others stand together against hate, build bridges, and heal divides. Service unites people regardless of race, ability, religion, or zip code. Now is the time to act on Dr. King’s “fierce urgency of now” and deliver on the promise of a Beloved Community. 

Remember, no act of kindness is too small. How are you serving your community today?

#MLKDay #BelovedCommunity #IServed

Metric
Company Name	Myriad Genetics, Inc.	American Esoteric Laboratories (AEL)	Genome Medical	Ortho Clinical Diagnostics Holdings plc
Symbol	MYGN			OCDX
MSH ID	COM:MYRIAD	COM:AEL	COM:GENOMEMEDICAL	COM:ORTHOCLINICALDIAGNOSTICS
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical - Diagnostics & Research	Medical Diagnostics	Healthcare & Health Services	Medical - Diagnostics & Research
Country	US	US	US	US
Stage
Employee Count	2.70K		143	4.80K
Website	myriad.com	ael.com	genomemedical.com	orthoclinicaldiagnostics.com
LinkedIn			genome-medical
Founders

Metric
Market Cap	2.28B
Enterprise Value
Monthly Web Traffic	208.71K
Web Traffic Growth	0.45
Valuation
Raised Capital	90M

Metric
Revenue	678.40M	2.04B
Revenue (LTM)
Revenue (NTM)
Gross Profit	476.40M	1.04B
EBITDA	-67.80M	253.40M
Operating Income	-123.70M	120M
Net Income	-112M	-54.30M
EPS	-1.39	-0.23
Diluted EPS	-1.39	-0.22
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.69	0.51
Operating Profit Margin	-0.37	0.06
EBITDA Margin	-0.10	0.12
Net Profit Margin	-0.37	-0.03
Return on Equity	-0.25	0.18
Return on Assets	-0.15	-0.02
Return on Capital Employed	-0.18	0.04

COM:MYRIAD

Myriad Genetics

Last Close

15.12

22/11 21:00

Market Cap

2.28B

Beta: -

Volume Today

622.81K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.54	-76.49
P/B Ratio	2.63	10.12
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.58
EV Multiple	-7.65	-7.66

Metric
Days Sales Outstanding	57.25	45.96
Days Payables Outstanding	54.15	65.62
Days Inventory Outstanding	79.39	110.72
Operating Cycle	191.40	156.67
Cash Conversion Cycle	84.17	91.05
Asset Turnover	0.64	0.61

Metric
Operating Cash Flow	-110.90M	286.60M
Free Cash Flow	-184.20M	286.60M
Cash Flow to Debt	-0.11	0.13
Operating Cash Flow/Sales	-0.06	0.14
Free Cash Flow Yield	-0.08

Metric
Cash & Equivalents	132.10M	309.70M
Accounts Receivable	3.80M
Inventory	22M	305.40M
Goodwill	287.40M	573.60M
Debt to Capitalization	0.23	0.85
Debt to Assets	0.18	0.67
Current Ratio	1.27	1.75
Quick Ratio	1.15	0.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05
R&D to Revenue	0.12	0.06
SG&A to Revenue	0.94